id,Provider ID,Measure ID,Measure Name,Score,Sample
,340001,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340002,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340004,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340010,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340014,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340021,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340028,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340030,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340032,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340040,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340042,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340047,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340050,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340053,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340069,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340070,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340090,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340091,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340098,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340113,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340115,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340130,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340131,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340141,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340147,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340155,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340166,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,340173,EDV,"Emergency department volume-Very High (60,000+ patients annually)",60000,-999
,333301,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340001,OP_1,Median Time to Fibrinolysis,-999,-999
,340001,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340001,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340001,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340002,OP_1,Median Time to Fibrinolysis,-999,-999
,340002,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340002,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340002,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340002,OP_4,Aspirin at Arrival,-999,-999
,340002,OP_5,Median Time to ECG,-999,-999
,340003,OP_1,Median Time to Fibrinolysis,-999,-999
,340003,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340003,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340003,STK_4,Thrombolytic Therapy,-999,-999
,340003,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340003,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340004,OP_1,Median Time to Fibrinolysis,-999,-999
,340004,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340004,OP_23,Head CT results,-999,-999
,340004,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,340004,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340004,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340008,OP_1,Median Time to Fibrinolysis,-999,-999
,340008,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340008,OP_23,Head CT results,-999,-999
,340008,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340008,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340008,STK_4,Thrombolytic Therapy,-999,-999
,340008,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340008,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340010,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340010,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340010,STK_4,Thrombolytic Therapy,-999,-999
,340013,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340013,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340013,STK_4,Thrombolytic Therapy,-999,-999
,340013,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340013,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340014,OP_1,Median Time to Fibrinolysis,-999,-999
,340014,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340014,OP_23,Head CT results,-999,-999
,340014,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340014,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340015,OP_1,Median Time to Fibrinolysis,-999,-999
,340015,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340015,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340015,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340015,STK_4,Thrombolytic Therapy,-999,-999
,340016,OP_1,Median Time to Fibrinolysis,-999,-999
,340016,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340016,OP_23,Head CT results,-999,-999
,340016,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340016,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340016,STK_4,Thrombolytic Therapy,-999,-999
,340016,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340016,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340017,OP_1,Median Time to Fibrinolysis,-999,-999
,340017,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340017,OP_23,Head CT results,-999,-999
,340017,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340017,STK_4,Thrombolytic Therapy,-999,-999
,340017,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340020,OP_1,Median Time to Fibrinolysis,-999,-999
,340020,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340020,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,340020,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,340020,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340020,STK_4,Thrombolytic Therapy,-999,-999
,340020,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340020,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340021,OP_1,Median Time to Fibrinolysis,-999,-999
,340021,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340021,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340021,STK_4,Thrombolytic Therapy,-999,-999
,340021,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340023,OP_1,Median Time to Fibrinolysis,-999,-999
,340023,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340023,OP_23,Head CT results,-999,-999
,340023,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340023,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340023,STK_4,Thrombolytic Therapy,-999,-999
,340023,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340023,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340024,OP_1,Median Time to Fibrinolysis,-999,-999
,340024,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340024,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340024,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340024,STK_4,Thrombolytic Therapy,-999,-999
,340024,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340024,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340027,OP_1,Median Time to Fibrinolysis,-999,-999
,340027,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340027,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,340027,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,340027,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340027,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340027,STK_4,Thrombolytic Therapy,-999,-999
,340028,OP_1,Median Time to Fibrinolysis,-999,-999
,340028,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340028,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340028,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340028,OP_4,Aspirin at Arrival,-999,-999
,340030,OP_1,Median Time to Fibrinolysis,-999,-999
,340030,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340030,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340030,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340030,OP_4,Aspirin at Arrival,-999,-999
,340030,OP_5,Median Time to ECG,-999,-999
,340032,OP_1,Median Time to Fibrinolysis,-999,-999
,340032,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340032,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340032,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340037,OP_1,Median Time to Fibrinolysis,-999,-999
,340037,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340037,OP_23,Head CT results,-999,-999
,340037,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,340037,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,340037,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340037,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,340037,STK_4,Thrombolytic Therapy,-999,-999
,340037,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340039,OP_1,Median Time to Fibrinolysis,-999,-999
,340039,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340039,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340039,STK_4,Thrombolytic Therapy,-999,-999
,340040,OP_1,Median Time to Fibrinolysis,-999,-999
,340040,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340040,OP_23,Head CT results,-999,-999
,340040,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340040,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340040,OP_4,Aspirin at Arrival,-999,-999
,340040,OP_5,Median Time to ECG,-999,-999
,340041,OP_1,Median Time to Fibrinolysis,-999,-999
,340041,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340041,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340041,STK_4,Thrombolytic Therapy,-999,-999
,340041,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340042,OP_1,Median Time to Fibrinolysis,-999,-999
,340042,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340042,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340042,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340042,STK_4,Thrombolytic Therapy,-999,-999
,340042,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340047,OP_1,Median Time to Fibrinolysis,-999,-999
,340047,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340047,OP_23,Head CT results,-999,-999
,340047,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340047,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340047,OP_4,Aspirin at Arrival,-999,-999
,340047,OP_5,Median Time to ECG,-999,-999
,340047,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,340049,ED_1b,ED1,-999,-999
,340049,ED_2b,ED2,-999,-999
,340049,EDV,Emergency department volume,-999,
,340049,OP_1,Median Time to Fibrinolysis,-999,-999
,340049,OP_18b,OP 18,-999,-999
,340049,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340049,OP_20,Door to diagnostic eval,-999,-999
,340049,OP_21,Median time to pain med,-999,-999
,340049,OP_22,Left before being seen,-999,-999
,340049,OP_23,Head CT results,-999,-999
,340049,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,340049,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,340049,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340049,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340049,OP_4,Aspirin at Arrival,-999,-999
,340049,OP_5,Median Time to ECG,-999,-999
,340049,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,340049,STK_4,Thrombolytic Therapy,-999,-999
,340049,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340049,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340050,OP_1,Median Time to Fibrinolysis,-999,-999
,340050,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340050,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340050,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340051,OP_1,Median Time to Fibrinolysis,-999,-999
,340051,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340051,OP_23,Head CT results,-999,-999
,340051,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340051,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340051,STK_4,Thrombolytic Therapy,-999,-999
,340051,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340053,OP_1,Median Time to Fibrinolysis,-999,-999
,340053,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340053,OP_23,Head CT results,-999,-999
,340053,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340053,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340053,OP_4,Aspirin at Arrival,-999,-999
,340053,OP_5,Median Time to ECG,-999,-999
,340060,OP_1,Median Time to Fibrinolysis,-999,-999
,340060,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340060,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340060,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340060,STK_4,Thrombolytic Therapy,-999,-999
,340060,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340060,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340061,OP_1,Median Time to Fibrinolysis,-999,-999
,340061,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340061,OP_23,Head CT results,-999,-999
,340061,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340061,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340061,OP_4,Aspirin at Arrival,-999,-999
,340061,OP_5,Median Time to ECG,-999,-999
,340064,OP_1,Median Time to Fibrinolysis,-999,-999
,340064,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340064,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340064,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340064,STK_4,Thrombolytic Therapy,-999,-999
,340064,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340064,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340068,OP_1,Median Time to Fibrinolysis,-999,-999
,340068,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340068,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340068,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340068,STK_4,Thrombolytic Therapy,-999,-999
,340068,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340068,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340069,OP_1,Median Time to Fibrinolysis,-999,-999
,340069,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340069,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340069,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340070,OP_1,Median Time to Fibrinolysis,-999,-999
,340070,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340070,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340070,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340070,STK_4,Thrombolytic Therapy,-999,-999
,340070,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340071,OP_1,Median Time to Fibrinolysis,-999,-999
,340071,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340071,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,340071,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340071,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340071,STK_4,Thrombolytic Therapy,-999,-999
,340071,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340073,OP_1,Median Time to Fibrinolysis,-999,-999
,340073,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340073,OP_23,Head CT results,-999,-999
,340073,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340073,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340073,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,340073,STK_4,Thrombolytic Therapy,-999,-999
,340075,OP_1,Median Time to Fibrinolysis,-999,-999
,340075,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340075,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340075,STK_4,Thrombolytic Therapy,-999,-999
,340075,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340084,OP_1,Median Time to Fibrinolysis,-999,-999
,340084,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340084,OP_23,Head CT results,-999,-999
,340084,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,340084,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340084,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,340084,STK_4,Thrombolytic Therapy,-999,-999
,340084,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340084,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340085,OP_1,Median Time to Fibrinolysis,-999,-999
,340085,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340085,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340085,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340085,STK_4,Thrombolytic Therapy,-999,-999
,340085,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340085,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340087,OP_1,Median Time to Fibrinolysis,-999,-999
,340087,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340087,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340087,STK_4,Thrombolytic Therapy,-999,-999
,340087,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340087,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340090,OP_1,Median Time to Fibrinolysis,-999,-999
,340090,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340090,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340090,STK_4,Thrombolytic Therapy,-999,-999
,340090,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340091,OP_1,Median Time to Fibrinolysis,-999,-999
,340091,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340091,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340091,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340096,OP_1,Median Time to Fibrinolysis,-999,-999
,340096,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340096,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340096,STK_4,Thrombolytic Therapy,-999,-999
,340096,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340096,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340097,OP_1,Median Time to Fibrinolysis,-999,-999
,340097,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340097,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340097,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340097,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340098,OP_1,Median Time to Fibrinolysis,-999,-999
,340098,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340098,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340098,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340098,STK_4,Thrombolytic Therapy,-999,-999
,340099,OP_1,Median Time to Fibrinolysis,-999,-999
,340099,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340099,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340099,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340099,STK_4,Thrombolytic Therapy,-999,-999
,340099,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340106,OP_1,Median Time to Fibrinolysis,-999,-999
,340106,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340106,OP_23,Head CT results,-999,-999
,340106,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340106,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340106,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,340106,STK_4,Thrombolytic Therapy,-999,-999
,340106,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340106,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340107,OP_23,Head CT results,-999,-999
,340107,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,340107,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340107,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340107,STK_4,Thrombolytic Therapy,-999,-999
,340107,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340109,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340109,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340109,STK_4,Thrombolytic Therapy,-999,-999
,340109,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340113,OP_1,Median Time to Fibrinolysis,-999,-999
,340113,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340113,OP_23,Head CT results,-999,-999
,340113,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340113,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340114,OP_1,Median Time to Fibrinolysis,-999,-999
,340114,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340114,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340114,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340114,OP_4,Aspirin at Arrival,-999,-999
,340114,OP_5,Median Time to ECG,-999,-999
,340115,OP_1,Median Time to Fibrinolysis,-999,-999
,340115,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340115,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340115,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340116,OP_1,Median Time to Fibrinolysis,-999,-999
,340116,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340116,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340116,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340116,OP_4,Aspirin at Arrival,-999,-999
,340116,OP_5,Median Time to ECG,-999,-999
,340119,OP_1,Median Time to Fibrinolysis,-999,-999
,340119,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340119,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340119,STK_4,Thrombolytic Therapy,-999,-999
,340119,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340120,OP_1,Median Time to Fibrinolysis,-999,-999
,340120,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340120,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340120,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340120,STK_4,Thrombolytic Therapy,-999,-999
,340120,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340120,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340123,OP_1,Median Time to Fibrinolysis,-999,-999
,340123,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340123,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340123,STK_4,Thrombolytic Therapy,-999,-999
,340123,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340126,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340126,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340126,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340127,OP_1,Median Time to Fibrinolysis,-999,-999
,340127,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340127,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340127,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340127,STK_4,Thrombolytic Therapy,-999,-999
,340127,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340127,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340129,OP_1,Median Time to Fibrinolysis,-999,-999
,340129,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340129,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340129,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340129,STK_4,Thrombolytic Therapy,-999,-999
,340129,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340130,OP_1,Median Time to Fibrinolysis,-999,-999
,340130,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340130,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340130,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340130,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340131,OP_1,Median Time to Fibrinolysis,-999,-999
,340131,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340131,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340131,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340131,OP_4,Aspirin at Arrival,-999,-999
,340131,OP_5,Median Time to ECG,-999,-999
,340131,STK_4,Thrombolytic Therapy,-999,-999
,340132,OP_1,Median Time to Fibrinolysis,-999,-999
,340132,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340132,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340132,STK_4,Thrombolytic Therapy,-999,-999
,340132,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340133,OP_1,Median Time to Fibrinolysis,-999,-999
,340133,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340133,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340133,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340133,STK_4,Thrombolytic Therapy,-999,-999
,340133,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340133,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340141,OP_1,Median Time to Fibrinolysis,-999,-999
,340141,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340141,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340141,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340141,OP_4,Aspirin at Arrival,-999,-999
,340141,OP_5,Median Time to ECG,-999,-999
,340142,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340142,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340142,STK_4,Thrombolytic Therapy,-999,-999
,340143,OP_1,Median Time to Fibrinolysis,-999,-999
,340143,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340143,OP_23,Head CT results,-999,-999
,340143,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340143,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340143,STK_4,Thrombolytic Therapy,-999,-999
,340143,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340144,OP_1,Median Time to Fibrinolysis,-999,-999
,340144,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340144,OP_23,Head CT results,-999,-999
,340144,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340144,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340144,STK_4,Thrombolytic Therapy,-999,-999
,340144,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340144,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340145,OP_1,Median Time to Fibrinolysis,-999,-999
,340145,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340145,OP_23,Head CT results,-999,-999
,340145,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340145,STK_4,Thrombolytic Therapy,-999,-999
,340145,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340145,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340147,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340147,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340148,ED_1b,ED1,-999,-999
,340148,ED_2b,ED2,-999,-999
,340148,EDV,Emergency department volume,-999,
,340148,OP_1,Median Time to Fibrinolysis,-999,-999
,340148,OP_18b,OP 18,-999,-999
,340148,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340148,OP_20,Door to diagnostic eval,-999,-999
,340148,OP_21,Median time to pain med,-999,-999
,340148,OP_22,Left before being seen,-999,-999
,340148,OP_23,Head CT results,-999,-999
,340148,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,340148,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,340148,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340148,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340148,OP_4,Aspirin at Arrival,-999,-999
,340148,OP_5,Median Time to ECG,-999,-999
,340148,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,340148,STK_4,Thrombolytic Therapy,-999,-999
,340148,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340148,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340151,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340151,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340151,STK_4,Thrombolytic Therapy,-999,-999
,340155,OP_1,Median Time to Fibrinolysis,-999,-999
,340155,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340155,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340155,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340156,EDV,Emergency department volume,-999,
,340156,OP_1,Median Time to Fibrinolysis,-999,-999
,340156,OP_18b,OP 18,-999,-999
,340156,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340156,OP_20,Door to diagnostic eval,-999,-999
,340156,OP_21,Median time to pain med,-999,-999
,340156,OP_22,Left before being seen,-999,-999
,340156,OP_23,Head CT results,-999,-999
,340156,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,340156,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,340156,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340156,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340156,OP_4,Aspirin at Arrival,-999,-999
,340156,OP_5,Median Time to ECG,-999,-999
,340156,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,340156,STK_4,Thrombolytic Therapy,-999,-999
,340156,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340156,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340158,OP_1,Median Time to Fibrinolysis,-999,-999
,340158,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340158,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340158,STK_4,Thrombolytic Therapy,-999,-999
,340158,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340158,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340159,OP_1,Median Time to Fibrinolysis,-999,-999
,340159,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340159,OP_23,Head CT results,-999,-999
,340159,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340159,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340159,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,340159,STK_4,Thrombolytic Therapy,-999,-999
,340159,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340159,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340166,OP_1,Median Time to Fibrinolysis,-999,-999
,340166,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340166,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340166,STK_4,Thrombolytic Therapy,-999,-999
,340166,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340168,ED_1b,ED1,-999,-999
,340168,ED_2b,ED2,-999,-999
,340168,EDV,Emergency department volume,-999,
,340168,IMM_2,Immunization for influenza,-999,-999
,340168,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,-999,-999
,340168,OP_1,Median Time to Fibrinolysis,-999,-999
,340168,OP_18b,OP 18,-999,-999
,340168,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340168,OP_20,Door to diagnostic eval,-999,-999
,340168,OP_21,Median time to pain med,-999,-999
,340168,OP_22,Left before being seen,-999,-999
,340168,OP_23,Head CT results,-999,-999
,340168,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,340168,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,340168,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340168,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340168,OP_4,Aspirin at Arrival,-999,-999
,340168,OP_5,Median Time to ECG,-999,-999
,340168,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,340168,STK_4,Thrombolytic Therapy,-999,-999
,340168,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340168,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340171,OP_1,Median Time to Fibrinolysis,-999,-999
,340171,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340171,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340171,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340171,STK_4,Thrombolytic Therapy,-999,-999
,340171,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340173,OP_1,Median Time to Fibrinolysis,-999,-999
,340173,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340173,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340173,STK_4,Thrombolytic Therapy,-999,-999
,340183,OP_1,Median Time to Fibrinolysis,-999,-999
,340183,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340183,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340183,STK_4,Thrombolytic Therapy,-999,-999
,340184,OP_1,Median Time to Fibrinolysis,-999,-999
,340184,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340184,OP_23,Head CT results,-999,-999
,340184,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340184,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340184,STK_4,Thrombolytic Therapy,-999,-999
,340184,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340186,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340186,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340186,STK_4,Thrombolytic Therapy,-999,-999
,340186,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340186,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340187,ED_1b,ED1,-999,-999
,340187,ED_2b,ED2,-999,-999
,340187,IMM_2,Immunization for influenza,-999,-999
,340187,OP_1,Median Time to Fibrinolysis,-999,-999
,340187,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340187,OP_23,Head CT results,-999,-999
,340187,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,340187,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,340187,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340187,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340187,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,340187,STK_4,Thrombolytic Therapy,-999,-999
,340187,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340187,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340188,EDV,Emergency department volume,-999,
,340188,OP_1,Median Time to Fibrinolysis,-999,-999
,340188,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340188,OP_22,Left before being seen,-999,-999
,340188,OP_23,Head CT results,-999,-999
,340188,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,340188,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,340188,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340188,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340188,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,340188,STK_4,Thrombolytic Therapy,-999,-999
,340188,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340188,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340189,ED_1b,ED1,-999,-999
,340189,ED_2b,ED2,-999,-999
,340189,EDV,Emergency department volume,-999,
,340189,IMM_2,Immunization for influenza,-999,-999
,340189,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,-999,-999
,340189,OP_1,Median Time to Fibrinolysis,-999,-999
,340189,OP_18b,OP 18,-999,-999
,340189,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,340189,OP_20,Door to diagnostic eval,-999,-999
,340189,OP_21,Median time to pain med,-999,-999
,340189,OP_22,Left before being seen,-999,-999
,340189,OP_23,Head CT results,-999,-999
,340189,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,340189,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,340189,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,340189,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,340189,OP_4,Aspirin at Arrival,-999,-999
,340189,OP_5,Median Time to ECG,-999,-999
,340189,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,340189,STK_4,Thrombolytic Therapy,-999,-999
,340189,VTE_5,Warfarin therapy discharge instructions,-999,-999
,340189,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341302,ED_1b,ED1,-999,-999
,341302,ED_2b,ED2,-999,-999
,341302,EDV,Emergency department volume,-999,
,341302,IMM_2,Immunization for influenza,-999,-999
,341302,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,-999,-999
,341302,OP_1,Median Time to Fibrinolysis,-999,-999
,341302,OP_18b,OP 18,-999,-999
,341302,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341302,OP_20,Door to diagnostic eval,-999,-999
,341302,OP_21,Median time to pain med,-999,-999
,341302,OP_22,Left before being seen,-999,-999
,341302,OP_23,Head CT results,-999,-999
,341302,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341302,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341302,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341302,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341302,OP_4,Aspirin at Arrival,-999,-999
,341302,OP_5,Median Time to ECG,-999,-999
,341302,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341302,STK_4,Thrombolytic Therapy,-999,-999
,341302,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341302,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341303,EDV,Emergency department volume,-999,
,341303,OP_1,Median Time to Fibrinolysis,-999,-999
,341303,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341303,OP_22,Left before being seen,-999,-999
,341303,OP_23,Head CT results,-999,-999
,341303,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341303,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341303,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341303,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341303,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341303,STK_4,Thrombolytic Therapy,-999,-999
,341303,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341303,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341304,OP_1,Median Time to Fibrinolysis,-999,-999
,341304,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341304,OP_23,Head CT results,-999,-999
,341304,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341304,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341304,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341304,STK_4,Thrombolytic Therapy,-999,-999
,341304,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341304,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341305,EDV,Emergency department volume,-999,
,341305,OP_1,Median Time to Fibrinolysis,-999,-999
,341305,OP_18b,OP 18,-999,-999
,341305,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341305,OP_20,Door to diagnostic eval,-999,-999
,341305,OP_21,Median time to pain med,-999,-999
,341305,OP_22,Left before being seen,-999,-999
,341305,OP_23,Head CT results,-999,-999
,341305,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341305,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341305,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341305,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341305,OP_4,Aspirin at Arrival,-999,-999
,341305,OP_5,Median Time to ECG,-999,-999
,341305,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341305,STK_4,Thrombolytic Therapy,-999,-999
,341305,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341305,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341307,EDV,Emergency department volume,-999,
,341307,IMM_2,Immunization for influenza,-999,-999
,341307,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,-999,-999
,341307,OP_1,Median Time to Fibrinolysis,-999,-999
,341307,OP_18b,OP 18,-999,-999
,341307,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341307,OP_20,Door to diagnostic eval,-999,-999
,341307,OP_21,Median time to pain med,-999,-999
,341307,OP_22,Left before being seen,-999,-999
,341307,OP_23,Head CT results,-999,-999
,341307,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341307,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341307,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341307,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341307,OP_4,Aspirin at Arrival,-999,-999
,341307,OP_5,Median Time to ECG,-999,-999
,341307,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341307,STK_4,Thrombolytic Therapy,-999,-999
,341307,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341307,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341311,EDV,Emergency department volume,-999,
,341311,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,-999,-999
,341311,OP_1,Median Time to Fibrinolysis,-999,-999
,341311,OP_18b,OP 18,-999,-999
,341311,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341311,OP_20,Door to diagnostic eval,-999,-999
,341311,OP_21,Median time to pain med,-999,-999
,341311,OP_22,Left before being seen,-999,-999
,341311,OP_23,Head CT results,-999,-999
,341311,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341311,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341311,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341311,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341311,OP_4,Aspirin at Arrival,-999,-999
,341311,OP_5,Median Time to ECG,-999,-999
,341311,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341311,STK_4,Thrombolytic Therapy,-999,-999
,341311,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341311,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341314,ED_1b,ED1,-999,-999
,341314,ED_2b,ED2,-999,-999
,341314,EDV,Emergency department volume,-999,
,341314,IMM_2,Immunization for influenza,-999,-999
,341314,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,-999,-999
,341314,OP_1,Median Time to Fibrinolysis,-999,-999
,341314,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341314,OP_21,Median time to pain med,-999,-999
,341314,OP_22,Left before being seen,-999,-999
,341314,OP_23,Head CT results,-999,-999
,341314,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341314,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341314,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341314,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341314,OP_4,Aspirin at Arrival,-999,-999
,341314,OP_5,Median Time to ECG,-999,-999
,341314,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341314,STK_4,Thrombolytic Therapy,-999,-999
,341314,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341314,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341315,EDV,Emergency department volume,-999,
,341315,OP_1,Median Time to Fibrinolysis,-999,-999
,341315,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341315,OP_22,Left before being seen,-999,-999
,341315,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341315,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341315,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341315,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341315,STK_4,Thrombolytic Therapy,-999,-999
,341315,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341315,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341316,EDV,Emergency department volume,-999,
,341316,OP_1,Median Time to Fibrinolysis,-999,-999
,341316,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341316,OP_22,Left before being seen,-999,-999
,341316,OP_23,Head CT results,-999,-999
,341316,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341316,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341316,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341316,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341316,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341316,STK_4,Thrombolytic Therapy,-999,-999
,341316,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341316,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341317,ED_1b,ED1,-999,-999
,341317,ED_2b,ED2,-999,-999
,341317,EDV,Emergency department volume,-999,
,341317,OP_1,Median Time to Fibrinolysis,-999,-999
,341317,OP_18b,OP 18,-999,-999
,341317,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341317,OP_20,Door to diagnostic eval,-999,-999
,341317,OP_21,Median time to pain med,-999,-999
,341317,OP_22,Left before being seen,-999,-999
,341317,OP_23,Head CT results,-999,-999
,341317,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341317,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341317,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341317,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341317,OP_4,Aspirin at Arrival,-999,-999
,341317,OP_5,Median Time to ECG,-999,-999
,341317,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341317,STK_4,Thrombolytic Therapy,-999,-999
,341317,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341317,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341318,OP_1,Median Time to Fibrinolysis,-999,-999
,341318,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341318,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341318,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341318,STK_4,Thrombolytic Therapy,-999,-999
,341318,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341318,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341319,OP_1,Median Time to Fibrinolysis,-999,-999
,341319,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341319,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341319,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341319,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341319,STK_4,Thrombolytic Therapy,-999,-999
,341319,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341320,EDV,Emergency department volume,-999,
,341320,IMM_2,Immunization for influenza,-999,-999
,341320,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,-999,-999
,341320,OP_1,Median Time to Fibrinolysis,-999,-999
,341320,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341320,OP_22,Left before being seen,-999,-999
,341320,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341320,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341320,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341320,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341320,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341320,STK_4,Thrombolytic Therapy,-999,-999
,341320,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341320,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341322,EDV,Emergency department volume,-999,
,341322,OP_1,Median Time to Fibrinolysis,-999,-999
,341322,OP_18b,OP 18,-999,-999
,341322,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341322,OP_20,Door to diagnostic eval,-999,-999
,341322,OP_21,Median time to pain med,-999,-999
,341322,OP_22,Left before being seen,-999,-999
,341322,OP_23,Head CT results,-999,-999
,341322,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341322,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341322,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341322,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341322,OP_4,Aspirin at Arrival,-999,-999
,341322,OP_5,Median Time to ECG,-999,-999
,341322,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341322,STK_4,Thrombolytic Therapy,-999,-999
,341322,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341322,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341323,ED_1b,ED1,-999,-999
,341323,ED_2b,ED2,-999,-999
,341323,EDV,Emergency department volume,-999,
,341323,OP_1,Median Time to Fibrinolysis,-999,-999
,341323,OP_18b,OP 18,-999,-999
,341323,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341323,OP_20,Door to diagnostic eval,-999,-999
,341323,OP_21,Median time to pain med,-999,-999
,341323,OP_22,Left before being seen,-999,-999
,341323,OP_23,Head CT results,-999,-999
,341323,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341323,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341323,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341323,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341323,OP_4,Aspirin at Arrival,-999,-999
,341323,OP_5,Median Time to ECG,-999,-999
,341323,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341323,STK_4,Thrombolytic Therapy,-999,-999
,341323,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341323,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341324,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341324,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341324,STK_4,Thrombolytic Therapy,-999,-999
,341324,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341324,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341325,EDV,Emergency department volume,-999,
,341325,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,-999,-999
,341325,OP_21,Median time to pain med,-999,-999
,341325,OP_22,Left before being seen,-999,-999
,341325,OP_23,Head CT results,-999,-999
,341325,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341325,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341325,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341325,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341325,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341325,STK_4,Thrombolytic Therapy,-999,-999
,341325,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341325,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341326,OP_1,Median Time to Fibrinolysis,-999,-999
,341326,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341326,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341326,STK_4,Thrombolytic Therapy,-999,-999
,341326,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341326,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341327,EDV,Emergency department volume,-999,
,341327,IMM_2,Immunization for influenza,-999,-999
,341327,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,-999,-999
,341327,OP_1,Median Time to Fibrinolysis,-999,-999
,341327,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341327,OP_22,Left before being seen,-999,-999
,341327,OP_23,Head CT results,-999,-999
,341327,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,-999,-999
,341327,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,-999,-999
,341327,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341327,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341327,STK_4,Thrombolytic Therapy,-999,-999
,341327,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341327,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341328,OP_1,Median Time to Fibrinolysis,-999,-999
,341328,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341328,OP_23,Head CT results,-999,-999
,341328,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341328,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341328,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",-999,-999
,341328,STK_4,Thrombolytic Therapy,-999,-999
,341328,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341328,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,341329,OP_1,Median Time to Fibrinolysis,-999,-999
,341329,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,-999,-999
,341329,OP_23,Head CT results,-999,-999
,341329,OP_31,Improvement in Patient???s Visual Function within 90 Days Following Cataract Surgery,-999,-999
,341329,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,-999,-999
,341329,STK_4,Thrombolytic Therapy,-999,-999
,341329,VTE_5,Warfarin therapy discharge instructions,-999,-999
,341329,VTE_6,Hospital acquired potentially preventable venous thromboembolism,-999,-999
,340003,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340013,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340017,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340020,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340023,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340024,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340037,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340041,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340051,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340060,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340064,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340068,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340085,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340087,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340096,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340097,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340099,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340107,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340119,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340120,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340127,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340129,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340132,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340144,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340158,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340159,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340183,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340184,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340186,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,341324,EDV,Emergency department volume,"Medium (20,000 - 39,999 patients annually)",
,340016,EDV,Emergency department volume,"Low (0 - 19,999 patients annually)",
,340084,EDV,Emergency department volume,"Low (0 - 19,999 patients annually)",
,340106,EDV,Emergency department volume,"Low (0 - 19,999 patients annually)",
,340133,EDV,Emergency department volume,"Low (0 - 19,999 patients annually)",
,340187,EDV,Emergency department volume,"Low (0 - 19,999 patients annually)",
,341304,EDV,Emergency department volume,"Low (0 - 19,999 patients annually)",
,341318,EDV,Emergency department volume,"Low (0 - 19,999 patients annually)",
,341319,EDV,Emergency department volume,"Low (0 - 19,999 patients annually)",
,341326,EDV,Emergency department volume,"Low (0 - 19,999 patients annually)",
,341328,EDV,Emergency department volume,"Low (0 - 19,999 patients annually)",
,341329,EDV,Emergency department volume,"Low (0 - 19,999 patients annually)",
,340008,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340015,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340027,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340039,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340061,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340071,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340073,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340075,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340109,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340114,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340116,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340123,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340126,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340142,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340143,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340145,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340151,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340171,EDV,Emergency department volume,"High (40,000 - 59,999 patients annually)",
,340042,ED_1b,ED1,492,1028
,340028,ED_1b,ED1,464,732
,340040,ED_1b,ED1,426,360
,340126,ED_1b,ED1,411,799
,340030,ED_1b,ED1,406,402
,340147,ED_1b,ED1,404,763
,340061,ED_1b,ED1,397,427
,341324,ED_1b,ED1,394,219
,340155,ED_1b,ED1,384,515
,341315,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,384,14
,340050,ED_1b,ED1,375,784
,340132,ED_1b,ED1,373,808
,340004,ED_1b,ED1,364,674
,340073,ED_1b,ED1,358,488
,340002,ED_1b,ED1,355,475
,340069,ED_1b,ED1,351,473
,340041,ED_1b,ED1,350,699
,340131,ED_1b,ED1,350,665
,340114,ED_1b,ED1,345,460
,340071,ED_1b,ED1,342,1038
,340085,ED_1b,ED1,340,532
,340008,ED_1b,ED1,338,744
,340047,ED_1b,ED1,335,782
,340084,ED_1b,ED1,335,66
,340173,ED_1b,ED1,328,499
,340091,ED_1b,ED1,318,700
,340119,ED_1b,ED1,318,475
,340090,ED_1b,ED1,313,620
,341318,ED_1b,ED1,312,274
,340032,ED_1b,ED1,310,835
,340014,ED_1b,ED1,308,1090
,340115,ED_1b,ED1,306,926
,340171,ED_1b,ED1,306,672
,340113,ED_1b,ED1,304,315
,340107,ED_1b,ED1,302,501
,340001,ED_1b,ED1,301,411
,340142,ED_1b,ED1,301,737
,340184,ED_1b,ED1,300,771
,340106,ED_1b,ED1,298,345
,340024,ED_1b,ED1,297,458
,341315,ED_1b,ED1,294,382
,340109,ED_1b,ED1,293,759
,340127,ED_1b,ED1,293,717
,341311,ED_1b,ED1,293,498
,340060,ED_1b,ED1,292,413
,340130,ED_1b,ED1,291,451
,340133,ED_1b,ED1,290,446
,340141,ED_1b,ED1,289,413
,340116,ED_1b,ED1,288,867
,340166,ED_1b,ED1,287,424
,340120,ED_1b,ED1,282,298
,340068,ED_1b,ED1,281,512
,340003,ED_1b,ED1,280,597
,340017,ED_1b,ED1,278,854
,340070,ED_1b,ED1,277,835
,340188,ED_1b,ED1,276,468
,340030,OP_18b,OP 18,275,355
,340151,ED_1b,ED1,272,981
,341328,ED_1b,ED1,272,734
,340015,ED_1b,ED1,271,979
,340097,ED_1b,ED1,271,727
,340075,ED_1b,ED1,267,439
,340144,ED_1b,ED1,267,405
,340020,ED_1b,ED1,266,766
,340131,OP_18b,OP 18,265,547
,340027,ED_1b,ED1,264,868
,340186,ED_1b,ED1,264,372
,341326,ED_1b,ED1,263,329
,340010,ED_1b,ED1,262,648
,340023,ED_1b,ED1,262,316
,340099,ED_1b,ED1,262,432
,340158,ED_1b,ED1,262,713
,340053,ED_1b,ED1,261,544
,340013,ED_1b,ED1,258,542
,340096,ED_1b,ED1,250,412
,340061,ED_2b,ED2,249,427
,340143,ED_1b,ED1,249,566
,340087,ED_1b,ED1,248,464
,340098,ED_1b,ED1,246,454
,340039,ED_1b,ED1,243,785
,341327,ED_1b,ED1,241,373
,340051,ED_1b,ED1,240,448
,340129,ED_1b,ED1,237,570
,340183,ED_1b,ED1,237,629
,340123,ED_1b,ED1,234,805
,340159,ED_1b,ED1,232,527
,340114,ED_2b,ED2,231,457
,341316,ED_1b,ED1,231,101
,340021,ED_1b,ED1,230,533
,340145,ED_1b,ED1,229,494
,340042,ED_2b,ED2,228,1028
,340064,ED_1b,ED1,228,503
,340126,ED_2b,ED2,228,798
,340156,ED_1b,ED1,228,256
,341322,ED_1b,ED1,226,391
,340016,ED_1b,ED1,224,486
,340040,ED_2b,ED2,223,358
,341307,ED_1b,ED1,223,467
,340002,OP_18b,OP 18,221,366
,340028,ED_2b,ED2,221,732
,341325,ED_1b,ED1,221,442
,340037,ED_1b,ED1,214,377
,341304,ED_1b,ED1,214,210
,341329,ED_1b,ED1,212,381
,340050,OP_18b,OP 18,208,347
,340042,OP_18b,OP 18,207,1675
,340171,OP_18b,OP 18,206,429
,341303,ED_1b,ED1,206,226
,340142,OP_18b,OP 18,205,376
,341305,ED_1b,ED1,204,267
,340040,OP_18b,OP 18,201,389
,340061,OP_18b,OP 18,200,359
,341319,ED_1b,ED1,200,561
,340132,OP_18b,OP 18,193,380
,340041,ED_2b,ED2,192,692
,340113,OP_18b,OP 18,192,380
,340073,ED_2b,ED2,190,485
,340114,OP_18b,OP 18,190,372
,340147,ED_2b,ED2,188,760
,340107,OP_18b,OP 18,186,376
,341320,ED_1b,ED1,183,382
,340116,OP_18b,OP 18,182,460
,340001,OP_18b,OP 18,180,406
,340047,OP_18b,OP 18,180,565
,340098,OP_18b,OP 18,180,406
,340155,ED_2b,ED2,180,512
,340070,OP_18b,OP 18,178,461
,340173,OP_18b,OP 18,177,439
,340147,OP_18b,OP 18,174,726
,340155,OP_18b,OP 18,174,370
,340091,OP_18b,OP 18,173,467
,340119,OP_18b,OP 18,173,377
,340017,OP_18b,OP 18,172,362
,340028,OP_18b,OP 18,172,357
,340085,OP_18b,OP 18,172,450
,340123,OP_18b,OP 18,172,380
,340183,OP_18b,OP 18,172,459
,340008,ED_2b,ED2,171,743
,340053,OP_18b,OP 18,168,455
,340069,OP_18b,OP 18,168,436
,340151,OP_18b,OP 18,168,1106
,340186,OP_18b,OP 18,168,372
,340071,ED_2b,ED2,167,1034
,340014,OP_18b,OP 18,166,1352
,340188,OP_18b,OP 18,166,311
,341315,OP_18b,OP 18,166,342
,341324,OP_18b,OP 18,166,363
,340127,OP_18b,OP 18,165,568
,340039,OP_18b,OP 18,164,389
,340166,OP_18b,OP 18,164,424
,340003,OP_18b,OP 18,160,466
,340004,OP_18b,OP 18,160,349
,340032,OP_18b,OP 18,160,351
,340050,ED_2b,ED2,160,780
,340090,OP_18b,OP 18,160,371
,340120,ED_2b,ED2,159,298
,340023,OP_18b,OP 18,158,418
,340126,OP_18b,OP 18,158,383
,340141,OP_18b,OP 18,158,383
,340087,OP_18b,OP 18,157,357
,340051,OP_18b,OP 18,156,348
,340068,OP_18b,OP 18,156,368
,340013,OP_18b,OP 18,154,418
,340145,OP_18b,OP 18,154,415
,340173,ED_2b,ED2,154,499
,341327,OP_18b,OP 18,154,284
,340084,OP_18b,OP 18,152,365
,340096,OP_18b,OP 18,152,354
,340097,OP_18b,OP 18,152,1394
,340184,OP_18b,OP 18,152,416
,340141,ED_2b,ED2,151,413
,340015,OP_18b,OP 18,150,449
,340143,OP_18b,OP 18,150,484
,341328,OP_18b,OP 18,150,942
,341318,OP_18b,OP 18,146,368
,340020,OP_18b,OP 18,145,434
,340002,ED_2b,ED2,144,474
,340132,ED_2b,ED2,144,806
,340184,ED_2b,ED2,143,771
,340115,OP_18b,OP 18,142,417
,340133,OP_18b,OP 18,142,386
,340008,OP_18b,OP 18,140,379
,340024,OP_18b,OP 18,140,427
,340027,OP_18b,OP 18,140,586
,340060,OP_18b,OP 18,139,397
,340069,ED_2b,ED2,139,473
,340130,OP_18b,OP 18,139,412
,341325,OP_18b,OP 18,139,370
,340010,OP_18b,OP 18,138,405
,340041,OP_18b,OP 18,137,359
,340064,OP_18b,OP 18,137,353
,340158,OP_18b,OP 18,137,448
,340071,OP_18b,OP 18,136,550
,341326,OP_18b,OP 18,135,376
,340073,OP_18b,OP 18,134,368
,340075,OP_18b,OP 18,134,414
,340144,OP_18b,OP 18,134,389
,340115,ED_2b,ED2,130,922
,341319,OP_18b,OP 18,130,374
,340099,OP_18b,OP 18,128,376
,340109,OP_18b,OP 18,128,2766
,341316,OP_18b,OP 18,124,200
,340016,OP_18b,OP 18,122,399
,340129,OP_18b,OP 18,122,396
,340032,ED_2b,ED2,121,830
,340060,ED_2b,ED2,120,413
,340116,ED_2b,ED2,120,866
,340020,ED_2b,ED2,118,766
,340004,ED_2b,ED2,117,674
,340021,OP_18b,OP 18,115,422
,340068,ED_2b,ED2,115,494
,340106,OP_18b,OP 18,115,379
,340097,ED_2b,ED2,114,727
,341329,OP_18b,OP 18,113,375
,340091,ED_2b,ED2,112,691
,340159,OP_18b,OP 18,112,382
,340013,ED_2b,ED2,111,519
,340075,ED_2b,ED2,111,434
,340120,OP_18b,OP 18,110,381
,340047,ED_2b,ED2,108,780
,340119,ED_2b,ED2,107,471
,340187,OP_18b,OP 18,106,516
,340037,OP_18b,OP 18,104,416
,341324,ED_2b,ED2,103,217
,340085,ED_2b,ED2,102,525
,341304,OP_18b,OP 18,102,371
,340001,STK_4,Thrombolytic Therapy,100,38
,340002,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,72
,340003,IMM_2,Immunization for influenza,100,382
,340003,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,407
,340003,OP_4,Aspirin at Arrival,100,184
,340004,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,67
,340004,OP_4,Aspirin at Arrival,100,17
,340004,VTE_5,Warfarin therapy discharge instructions,100,53
,340010,VTE_5,Warfarin therapy discharge instructions,100,13
,340014,IMM_2,Immunization for influenza,100,987
,340014,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,90
,340014,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,214
,340014,OP_4,Aspirin at Arrival,100,85
,340014,VTE_5,Warfarin therapy discharge instructions,100,68
,340015,IMM_2,Immunization for influenza,100,671
,340015,OP_4,Aspirin at Arrival,100,13
,340015,VTE_5,Warfarin therapy discharge instructions,100,30
,340017,OP_4,Aspirin at Arrival,100,93
,340021,OP_4,Aspirin at Arrival,100,146
,340027,OP_4,Aspirin at Arrival,100,70
,340028,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,44
,340028,VTE_5,Warfarin therapy discharge instructions,100,43
,340030,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,16
,340032,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,63
,340032,STK_4,Thrombolytic Therapy,100,21
,340037,VTE_5,Warfarin therapy discharge instructions,100,12
,340039,VTE_5,Warfarin therapy discharge instructions,100,36
,340041,IMM_2,Immunization for influenza,100,519
,340041,VTE_5,Warfarin therapy discharge instructions,100,19
,340042,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,156
,340047,STK_4,Thrombolytic Therapy,100,37
,340047,VTE_5,Warfarin therapy discharge instructions,100,168
,340049,IMM_2,Immunization for influenza,100,306
,340050,OP_4,Aspirin at Arrival,100,18
,340051,OP_4,Aspirin at Arrival,100,60
,340051,VTE_5,Warfarin therapy discharge instructions,100,13
,340053,STK_4,Thrombolytic Therapy,100,29
,340053,VTE_5,Warfarin therapy discharge instructions,100,47
,340060,IMM_2,Immunization for influenza,100,267
,340061,STK_4,Thrombolytic Therapy,100,11
,340061,VTE_5,Warfarin therapy discharge instructions,100,52
,340064,OP_4,Aspirin at Arrival,100,141
,340068,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,656
,340068,OP_4,Aspirin at Arrival,100,91
,340069,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,9764
,340069,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,87
,340070,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,134
,340070,OP_4,Aspirin at Arrival,100,69
,340071,OP_4,Aspirin at Arrival,100,362
,340071,VTE_5,Warfarin therapy discharge instructions,100,13
,340073,IMM_2,Immunization for influenza,100,605
,340073,VTE_5,Warfarin therapy discharge instructions,100,22
,340075,VTE_5,Warfarin therapy discharge instructions,100,17
,340085,IMM_2,Immunization for influenza,100,373
,340085,OP_23,Head CT results,100,12
,340085,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,66
,340085,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,122
,340085,OP_4,Aspirin at Arrival,100,54
,340087,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,54
,340090,OP_4,Aspirin at Arrival,100,269
,340091,OP_4,Aspirin at Arrival,100,35
,340096,IMM_2,Immunization for influenza,100,282
,340096,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,70
,340097,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,977
,340097,STK_4,Thrombolytic Therapy,100,11
,340097,VTE_5,Warfarin therapy discharge instructions,100,14
,340099,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,921
,340106,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,51
,340106,OP_4,Aspirin at Arrival,100,19
,340107,OP_4,Aspirin at Arrival,100,119
,340107,VTE_5,Warfarin therapy discharge instructions,100,11
,340109,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,107
,340113,ED_2b,ED2,100,313
,340114,STK_4,Thrombolytic Therapy,100,13
,340115,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,5712
,340115,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,67
,340115,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,57
,340115,STK_4,Thrombolytic Therapy,100,31
,340116,STK_4,Thrombolytic Therapy,100,12
,340116,VTE_5,Warfarin therapy discharge instructions,100,26
,340120,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,50
,340126,VTE_5,Warfarin therapy discharge instructions,100,28
,340127,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,386
,340127,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,112
,340129,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,80
,340129,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,204
,340130,STK_4,Thrombolytic Therapy,100,13
,340131,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,52
,340131,VTE_5,Warfarin therapy discharge instructions,100,25
,340133,OP_4,Aspirin at Arrival,100,57
,340142,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,33
,340142,VTE_5,Warfarin therapy discharge instructions,100,23
,340143,VTE_5,Warfarin therapy discharge instructions,100,21
,340144,IMM_2,Immunization for influenza,100,287
,340144,OP_4,Aspirin at Arrival,100,16
,340148,IMM_2,Immunization for influenza,100,445
,340151,OP_23,Head CT results,100,29
,340151,VTE_5,Warfarin therapy discharge instructions,100,34
,340155,VTE_5,Warfarin therapy discharge instructions,100,58
,340158,OP_23,Head CT results,100,17
,340158,OP_4,Aspirin at Arrival,100,50
,340159,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,100
,340166,VTE_5,Warfarin therapy discharge instructions,100,11
,340171,VTE_5,Warfarin therapy discharge instructions,100,21
,340173,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,191
,340173,VTE_5,Warfarin therapy discharge instructions,100,35
,340183,IMM_2,Immunization for influenza,100,516
,340183,OP_4,Aspirin at Arrival,100,50
,340183,VTE_5,Warfarin therapy discharge instructions,100,18
,340184,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,155
,340184,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,94
,340184,VTE_5,Warfarin therapy discharge instructions,100,16
,340186,IMM_2,Immunization for influenza,100,269
,341303,OP_4,Aspirin at Arrival,100,38
,341304,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,238
,341315,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,497
,341318,IMM_2,Immunization for influenza,100,237
,341318,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,96
,341319,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,72
,341320,OP_4,Aspirin at Arrival,100,21
,341325,OP_4,Aspirin at Arrival,100,125
,341326,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,66
,341329,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,20
,341329,OP_4,Aspirin at Arrival,100,120
,340001,VTE_5,Warfarin therapy discharge instructions,99,79
,340003,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,172
,340008,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,1396
,340013,OP_4,Aspirin at Arrival,99,132
,340014,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,6546
,340015,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,90
,340017,IMM_2,Immunization for influenza,99,563
,340020,OP_4,Aspirin at Arrival,99,122
,340021,IMM_2,Immunization for influenza,99,534
,340028,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,6158
,340030,ED_2b,ED2,99,395
,340030,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,12111
,340032,IMM_2,Immunization for influenza,99,562
,340037,IMM_2,Immunization for influenza,99,296
,340037,OP_4,Aspirin at Arrival,99,105
,340040,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,10044
,340041,OP_4,Aspirin at Arrival,99,86
,340050,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,2211
,340051,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,99,294
,340053,IMM_2,Immunization for influenza,99,1004
,340060,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,870
,340061,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,99,97
,340064,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,90
,340069,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,171
,340071,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,1155
,340075,IMM_2,Immunization for influenza,99,522
,340087,OP_4,Aspirin at Arrival,99,163
,340090,IMM_2,Immunization for influenza,99,490
,340099,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,99,129
,340107,IMM_2,Immunization for influenza,99,325
,340107,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,699
,340114,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,8219
,340120,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,113
,340123,IMM_2,Immunization for influenza,99,509
,340123,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,1872
,340126,IMM_2,Immunization for influenza,99,501
,340127,OP_4,Aspirin at Arrival,99,114
,340129,IMM_2,Immunization for influenza,99,501
,340130,ED_2b,ED2,99,451
,340131,ED_2b,ED2,99,636
,340131,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,3159
,340132,IMM_2,Immunization for influenza,99,491
,340132,OP_4,Aspirin at Arrival,99,172
,340133,IMM_2,Immunization for influenza,99,277
,340141,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,7365
,340142,OP_4,Aspirin at Arrival,99,94
,340143,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,2277
,340145,OP_4,Aspirin at Arrival,99,181
,340151,OP_4,Aspirin at Arrival,99,236
,340155,IMM_2,Immunization for influenza,99,564
,340155,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,3730
,340158,IMM_2,Immunization for influenza,99,477
,340159,OP_4,Aspirin at Arrival,99,143
,340171,IMM_2,Immunization for influenza,99,524
,340173,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,2814
,340184,IMM_2,Immunization for influenza,99,442
,340184,OP_4,Aspirin at Arrival,99,93
,340186,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,966
,340186,OP_4,Aspirin at Arrival,99,227
,341304,IMM_2,Immunization for influenza,99,185
,341305,IMM_2,Immunization for influenza,99,142
,341318,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,592
,341318,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,103
,341318,OP_4,Aspirin at Arrival,99,148
,341324,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,99,104
,341328,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,89
,341328,OP_4,Aspirin at Arrival,99,137
,340004,IMM_2,Immunization for influenza,98,546
,340008,OP_4,Aspirin at Arrival,98,49
,340010,IMM_2,Immunization for influenza,98,486
,340010,OP_4,Aspirin at Arrival,98,268
,340015,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,1649
,340015,OP_23,Head CT results,98,46
,340023,OP_4,Aspirin at Arrival,98,49
,340028,IMM_2,Immunization for influenza,98,497
,340030,VTE_5,Warfarin therapy discharge instructions,98,85
,340039,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,1806
,340039,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,98,100
,340047,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,98,248
,340049,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,474
,340051,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,914
,340061,IMM_2,Immunization for influenza,98,503
,340064,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,98,124
,340068,IMM_2,Immunization for influenza,98,356
,340069,IMM_2,Immunization for influenza,98,515
,340069,VTE_5,Warfarin therapy discharge instructions,98,66
,340073,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,2487
,340085,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,798
,340090,ED_2b,ED2,98,617
,340090,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,98,63
,340096,OP_4,Aspirin at Arrival,98,129
,340097,OP_4,Aspirin at Arrival,98,169
,340098,IMM_2,Immunization for influenza,98,514
,340098,VTE_5,Warfarin therapy discharge instructions,98,41
,340114,IMM_2,Immunization for influenza,98,545
,340114,VTE_5,Warfarin therapy discharge instructions,98,48
,340115,IMM_2,Immunization for influenza,98,578
,340116,IMM_2,Immunization for influenza,98,625
,340119,IMM_2,Immunization for influenza,98,328
,340120,OP_4,Aspirin at Arrival,98,126
,340126,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,1654
,340127,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,726
,340130,IMM_2,Immunization for influenza,98,544
,340132,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,98,102
,340148,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,720
,340151,IMM_2,Immunization for influenza,98,669
,340151,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,990
,340158,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,888
,340159,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,333
,340159,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,98,103
,340173,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,98,41
,340183,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,1584
,341303,IMM_2,Immunization for influenza,98,121
,341303,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,290
,341304,OP_4,Aspirin at Arrival,98,51
,341319,OP_4,Aspirin at Arrival,98,141
,341322,IMM_2,Immunization for influenza,98,343
,341323,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,289
,341324,OP_4,Aspirin at Arrival,98,185
,341326,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,737
,341326,OP_4,Aspirin at Arrival,98,138
,340001,IMM_2,Immunization for influenza,97,535
,340004,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,3308
,340014,STK_4,Thrombolytic Therapy,97,78
,340016,IMM_2,Immunization for influenza,97,402
,340020,IMM_2,Immunization for influenza,97,495
,340030,IMM_2,Immunization for influenza,97,531
,340032,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,63
,340050,IMM_2,Immunization for influenza,97,554
,340061,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,15337
,340084,IMM_2,Immunization for influenza,97,71
,340090,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,97,64
,340091,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,11264
,340097,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,248
,340098,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,86
,340099,IMM_2,Immunization for influenza,97,289
,340099,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,97,105
,340113,IMM_2,Immunization for influenza,97,531
,340113,STK_4,Thrombolytic Therapy,97,30
,340119,OP_4,Aspirin at Arrival,97,113
,340120,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,632
,340123,OP_4,Aspirin at Arrival,97,106
,340130,OP_4,Aspirin at Arrival,97,144
,340131,IMM_2,Immunization for influenza,97,559
,340132,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,97,100
,340143,OP_4,Aspirin at Arrival,97,29
,340147,OP_4,Aspirin at Arrival,97,179
,340147,VTE_5,Warfarin therapy discharge instructions,97,38
,340155,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,75
,340156,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,538
,340158,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,66
,340166,IMM_2,Immunization for influenza,97,476
,340166,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,59
,340171,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,1869
,340186,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,120
,341311,IMM_2,Immunization for influenza,97,236
,341315,OP_4,Aspirin at Arrival,97,75
,341324,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,656
,341326,IMM_2,Immunization for influenza,97,234
,341329,IMM_2,Immunization for influenza,97,245
,340001,OP_4,Aspirin at Arrival,96,54
,340002,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,11393
,340008,IMM_2,Immunization for influenza,96,483
,340013,IMM_2,Immunization for influenza,96,360
,340020,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,913
,340021,VTE_5,Warfarin therapy discharge instructions,96,23
,340024,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,759
,340027,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,1698
,340032,VTE_5,Warfarin therapy discharge instructions,96,111
,340039,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,96,158
,340040,IMM_2,Immunization for influenza,96,526
,340040,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,96,27
,340042,IMM_2,Immunization for influenza,96,831
,340053,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,5172
,340069,STK_4,Thrombolytic Therapy,96,55
,340070,ED_2b,ED2,96,835
,340070,IMM_2,Immunization for influenza,96,548
,340070,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,3289
,340084,OP_4,Aspirin at Arrival,96,213
,340098,OP_4,Aspirin at Arrival,96,83
,340106,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,96,71
,340109,IMM_2,Immunization for influenza,96,494
,340113,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,96,383
,340119,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,937
,340126,OP_4,Aspirin at Arrival,96,151
,340129,OP_4,Aspirin at Arrival,96,45
,340132,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,1000
,340133,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,96,24
,340143,IMM_2,Immunization for influenza,96,493
,340145,IMM_2,Immunization for influenza,96,453
,340147,IMM_2,Immunization for influenza,96,577
,340155,STK_4,Thrombolytic Therapy,96,23
,340173,IMM_2,Immunization for influenza,96,488
,340173,OP_23,Head CT results,96,27
,340186,ED_2b,ED2,96,371
,341315,IMM_2,Immunization for influenza,96,257
,341316,OP_4,Aspirin at Arrival,96,28
,341324,IMM_2,Immunization for influenza,96,227
,341324,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,96,115
,341325,IMM_2,Immunization for influenza,96,271
,341327,OP_4,Aspirin at Arrival,96,51
,341328,IMM_2,Immunization for influenza,96,382
,340002,IMM_2,Immunization for influenza,95,546
,340002,STK_4,Thrombolytic Therapy,95,19
,340003,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,1023
,340004,STK_4,Thrombolytic Therapy,95,19
,340010,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,2727
,340017,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,95,138
,340020,OP_23,Head CT results,95,19
,340021,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,95,55
,340023,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,1262
,340027,IMM_2,Immunization for influenza,95,508
,340027,OP_23,Head CT results,95,22
,340032,OP_4,Aspirin at Arrival,95,39
,340041,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,1099
,340060,OP_4,Aspirin at Arrival,95,110
,340064,IMM_2,Immunization for influenza,95,331
,340075,OP_4,Aspirin at Arrival,95,94
,340091,IMM_2,Immunization for influenza,95,568
,340096,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,964
,340099,OP_4,Aspirin at Arrival,95,109
,340106,IMM_2,Immunization for influenza,95,315
,340120,IMM_2,Immunization for influenza,95,230
,340126,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,95,59
,340144,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,95,20
,340147,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,2310
,340166,OP_4,Aspirin at Arrival,95,180
,340171,OP_4,Aspirin at Arrival,95,59
,340173,OP_4,Aspirin at Arrival,95,191
,340188,IMM_2,Immunization for influenza,95,146
,341304,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,95,37
,341304,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,95,19
,341316,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,249
,341328,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,95,150
,340016,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,94,1241
,340027,ED_2b,ED2,94,866
,340027,VTE_5,Warfarin therapy discharge instructions,94,32
,340039,OP_4,Aspirin at Arrival,94,72
,340042,OP_4,Aspirin at Arrival,94,287
,340051,IMM_2,Immunization for influenza,94,370
,340061,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,94,96
,340069,OP_4,Aspirin at Arrival,94,183
,340071,IMM_2,Immunization for influenza,94,580
,340073,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,94,16
,340087,IMM_2,Immunization for influenza,94,260
,340097,OP_23,Head CT results,94,16
,340109,OP_4,Aspirin at Arrival,94,128
,340131,OP_21,Median time to pain med,94,98
,340145,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,94,108
,340147,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,94,247
,340158,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,94,68
,340171,ED_2b,ED2,94,668
,341318,ED_2b,ED2,94,248
,340004,OP_21,Median time to pain med,93,168
,340016,OP_4,Aspirin at Arrival,93,86
,340017,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,93,155
,340028,STK_4,Thrombolytic Therapy,93,30
,340030,STK_4,Thrombolytic Therapy,93,43
,340039,IMM_2,Immunization for influenza,93,554
,340042,VTE_5,Warfarin therapy discharge instructions,93,15
,340051,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,93,89
,340068,OP_23,Head CT results,93,15
,340084,ED_2b,ED2,93,61
,340084,OP_21,Median time to pain med,93,37
,340087,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,93,1043
,340091,VTE_5,Warfarin therapy discharge instructions,93,82
,340097,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,93,119
,340113,OP_4,Aspirin at Arrival,93,188
,340113,VTE_5,Warfarin therapy discharge instructions,93,101
,340115,VTE_5,Warfarin therapy discharge instructions,93,44
,340119,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,93,193
,340141,STK_4,Thrombolytic Therapy,93,58
,340142,IMM_2,Immunization for influenza,93,489
,340151,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,93,15
,340155,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,93,71
,340186,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,93,191
,340187,OP_4,Aspirin at Arrival,93,177
,341319,IMM_2,Immunization for influenza,93,292
,341319,VTE_5,Warfarin therapy discharge instructions,93,15
,341328,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,93,685
,341329,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,93,764
,340002,VTE_5,Warfarin therapy discharge instructions,92,150
,340008,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,92,71
,340016,ED_2b,ED2,92,486
,340021,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,92,12
,340047,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,92,254
,340084,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,92,164
,340091,STK_4,Thrombolytic Therapy,92,61
,340099,VTE_5,Warfarin therapy discharge instructions,92,13
,340107,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,92,13
,340115,OP_4,Aspirin at Arrival,92,78
,340116,OP_23,Head CT results,92,37
,340116,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,92,84
,340127,IMM_2,Immunization for influenza,92,279
,340130,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,92,61
,340183,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,92,65
,340001,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,3460
,340001,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,91,81
,340016,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,91,98
,340017,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,1553
,340021,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,1273
,340032,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,3906
,340042,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,1989
,340047,IMM_2,Immunization for influenza,91,827
,340069,OP_23,Head CT results,91,35
,340090,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,3818
,340090,VTE_5,Warfarin therapy discharge instructions,91,11
,340091,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,91,115
,340107,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,91,11
,340109,ED_2b,ED2,91,759
,340127,OP_21,Median time to pain med,91,74
,340158,ED_2b,ED2,91,713
,340159,IMM_2,Immunization for influenza,91,265
,340187,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,272
,341319,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,932
,340003,OP_23,Head CT results,90,40
,340060,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,90,140
,340070,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,90,132
,340097,IMM_2,Immunization for influenza,90,419
,340113,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,90,355
,340127,ED_2b,ED2,90,717
,340141,IMM_2,Immunization for influenza,90,486
,340145,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,90,774
,340155,OP_4,Aspirin at Arrival,90,20
,340166,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,90,49
,340171,OP_23,Head CT results,90,30
,340188,OP_4,Aspirin at Arrival,90,71
,341305,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,90,99
,341323,IMM_2,Immunization for influenza,90,186
,340010,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,89,63
,340023,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,89,28
,340024,OP_4,Aspirin at Arrival,89,308
,340032,OP_23,Head CT results,89,28
,340047,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,89,18346
,340113,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,89,10966
,340119,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,89,118
,340119,VTE_5,Warfarin therapy discharge instructions,89,19
,340143,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,89,323
,340145,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,89,177
,341304,ED_2b,ED2,89,209
,341326,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,89,27
,340001,ED_2b,ED2,88,408
,340003,ED_2b,ED2,88,597
,340015,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,88,74
,340030,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,88,16
,340040,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,88,40
,340053,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,88,64
,340090,OP_23,Head CT results,88,16
,340126,OP_23,Head CT results,88,33
,340133,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,88,355
,340141,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,88,242
,340016,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,87,141
,340024,IMM_2,Immunization for influenza,87,285
,340037,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,87,376
,340109,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,87,1595
,340156,IMM_2,Immunization for influenza,87,163
,340008,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,86,64
,340023,IMM_2,Immunization for influenza,86,296
,340098,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,86,152
,340107,ED_2b,ED2,86,499
,340129,VTE_5,Warfarin therapy discharge instructions,86,22
,340141,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,86,99
,340166,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,86,1070
,340171,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,86,64
,341311,ED_2b,ED2,86,495
,341315,OP_21,Median time to pain med,86,94
,340013,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,85,937
,340023,ED_2b,ED2,85,315
,340040,VTE_5,Warfarin therapy discharge instructions,85,159
,340075,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,85,1843
,340096,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,85,75
,340120,OP_23,Head CT results,85,13
,340142,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,85,1480
,340151,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,85,34
,340184,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,85,1588
,341317,IMM_2,Immunization for influenza,85,131
,340001,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,84,101
,340017,VTE_5,Warfarin therapy discharge instructions,84,19
,340041,OP_21,Median time to pain med,84,82
,340041,OP_23,Head CT results,84,19
,340126,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,84,38
,340147,OP_23,Head CT results,84,31
,340151,ED_2b,ED2,84,979
,341319,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,84,67
,340002,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,83,54
,340040,STK_4,Thrombolytic Therapy,83,29
,340071,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,83,12
,340073,OP_21,Median time to pain med,83,151
,340099,ED_2b,ED2,83,431
,340116,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,83,2172
,340123,VTE_5,Warfarin therapy discharge instructions,83,12
,340130,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,83,1475
,341316,IMM_2,Immunization for influenza,83,30
,341322,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,83,397
,341326,OP_23,Head CT results,83,24
,340010,OP_23,Head CT results,82,11
,340014,ED_2b,ED2,82,1058
,340015,ED_2b,ED2,82,976
,340039,ED_2b,ED2,82,785
,340064,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,82,932
,340123,ED_2b,ED2,82,803
,340127,OP_23,Head CT results,82,11
,340129,OP_23,Head CT results,82,17
,340131,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,82,17
,340133,OP_23,Head CT results,82,11
,340142,OP_23,Head CT results,82,28
,340155,OP_23,Head CT results,82,11
,340042,OP_23,Head CT results,81,36
,340114,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,81,68
,340133,ED_2b,ED2,81,445
,340010,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,80,20
,340021,ED_2b,ED2,80,527
,340053,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,80,64
,340060,OP_21,Median time to pain med,80,90
,340091,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,80,129
,340098,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,80,2192
,340183,OP_23,Head CT results,80,20
,341303,OP_18b,OP 18,80,385
,341320,OP_18b,OP 18,80,361
,340041,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,79,58
,340050,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,79,61
,340106,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,79,349
,341319,OP_23,Head CT results,79,19
,340010,ED_2b,ED2,78,644
,340013,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,78,98
,340024,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,78,126
,340039,OP_23,Head CT results,78,32
,340053,ED_2b,ED2,78,544
,340068,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,78,46
,340106,ED_2b,ED2,78,345
,340107,OP_21,Median time to pain med,78,58
,340143,OP_21,Median time to pain med,78,262
,340144,ED_2b,ED2,78,405
,340064,OP_23,Head CT results,77,13
,340114,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,77,64
,340126,STK_4,Thrombolytic Therapy,77,13
,340188,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,77,409
,340010,OP_21,Median time to pain med,76,95
,340071,OP_23,Head CT results,76,38
,341307,ED_2b,ED2,76,464
,340013,OP_23,Head CT results,75,16
,340030,OP_21,Median time to pain med,75,535
,340073,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,75,12
,340087,OP_23,Head CT results,75,12
,340129,ED_2b,ED2,75,570
,340166,ED_2b,ED2,75,423
,340186,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,75,12
,341315,OP_20,Door to diagnostic eval,75,358
,341328,ED_2b,ED2,75,721
,340023,OP_21,Median time to pain med,74,155
,340024,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,74,115
,340132,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,74,19
,341326,ED_2b,ED2,74,329
,341327,ED_2b,ED2,74,371
,340024,OP_21,Median time to pain med,73,95
,340042,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,73,98
,340050,VTE_5,Warfarin therapy discharge instructions,72,64
,340060,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,72,229
,340116,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,72,46
,340141,VTE_5,Warfarin therapy discharge instructions,72,32
,340017,ED_2b,ED2,71,854
,340115,OP_23,Head CT results,71,17
,340119,OP_23,Head CT results,71,14
,341329,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,71,55
,340008,OP_21,Median time to pain med,70,168
,340071,OP_21,Median time to pain med,70,208
,340129,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,70,1186
,340142,OP_21,Median time to pain med,70,118
,341314,OP_18b,OP 18,70,368
,340013,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,69,13
,340060,OP_23,Head CT results,69,13
,340132,VTE_5,Warfarin therapy discharge instructions,69,13
,340151,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,69,16
,340008,OP_20,Door to diagnostic eval,68,383
,340037,OP_21,Median time to pain med,68,83
,340073,OP_4,Aspirin at Arrival,68,22
,340132,OP_21,Median time to pain med,68,98
,340132,OP_23,Head CT results,68,25
,340144,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,68,624
,340171,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,68,65
,340188,OP_21,Median time to pain med,68,54
,340087,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,67,45
,340096,OP_21,Median time to pain med,67,124
,340099,OP_23,Head CT results,67,12
,340141,OP_23,Head CT results,67,18
,340188,ED_2b,ED2,67,468
,341318,OP_23,Head CT results,67,21
,341328,OP_21,Median time to pain med,67,133
,340010,OP_20,Door to diagnostic eval,66,294
,340070,OP_21,Median time to pain med,66,218
,340075,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,66,222
,340096,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,66,17
,340130,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,66,99
,340027,OP_21,Median time to pain med,65,152
,340050,OP_21,Median time to pain med,65,143
,340142,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,65,34
,340159,ED_2b,ED2,65,524
,340004,OP_20,Door to diagnostic eval,64,406
,340021,OP_23,Head CT results,64,22
,340023,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,64,90
,340115,OP_21,Median time to pain med,64,274
,340116,OP_21,Median time to pain med,64,156
,340166,OP_23,Head CT results,64,25
,340001,OP_23,Head CT results,63,19
,340028,OP_23,Head CT results,63,19
,340061,OP_21,Median time to pain med,63,151
,340142,ED_2b,ED2,63,737
,340144,OP_21,Median time to pain med,63,85
,340147,OP_21,Median time to pain med,63,198
,340147,STK_4,Thrombolytic Therapy,63,19
,340173,OP_21,Median time to pain med,63,322
,340001,OP_21,Median time to pain med,62,351
,340032,OP_21,Median time to pain med,62,298
,340037,ED_2b,ED2,62,377
,340075,OP_21,Median time to pain med,62,201
,340123,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,62,68
,340130,OP_21,Median time to pain med,62,323
,341305,ED_2b,ED2,62,266
,341315,OP_23,Head CT results,62,13
,341324,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,62,16
,340109,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,61,23
,340123,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,61,64
,340126,OP_21,Median time to pain med,61,99
,340183,ED_2b,ED2,61,629
,340184,OP_21,Median time to pain med,61,220
,340002,OP_21,Median time to pain med,60,180
,340096,ED_2b,ED2,60,410
,340096,OP_23,Head CT results,60,20
,340141,OP_21,Median time to pain med,60,343
,340147,OP_20,Door to diagnostic eval,60,763
,341320,ED_2b,ED2,60,354
,340028,OP_21,Median time to pain med,59,245
,340091,OP_23,Head CT results,59,27
,340113,OP_21,Median time to pain med,59,666
,340119,OP_21,Median time to pain med,59,107
,340123,OP_23,Head CT results,59,17
,340051,OP_21,Median time to pain med,58,110
,340133,OP_21,Median time to pain med,58,72
,340166,OP_21,Median time to pain med,58,311
,341303,ED_2b,ED2,58,226
,340010,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,57,67
,340039,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,57,31
,340068,OP_21,Median time to pain med,57,113
,340075,OP_23,Head CT results,57,23
,340084,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,57,12
,340087,ED_2b,ED2,57,463
,340133,OP_20,Door to diagnostic eval,57,420
,340003,OP_21,Median time to pain med,56,95
,340039,OP_21,Median time to pain med,56,171
,340050,STK_4,Thrombolytic Therapy,56,18
,340145,ED_2b,ED2,56,494
,340151,OP_21,Median time to pain med,56,65
,340002,OP_23,Head CT results,55,11
,340070,OP_20,Door to diagnostic eval,55,475
,340087,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,55,11
,340123,OP_21,Median time to pain med,55,183
,340155,OP_21,Median time to pain med,55,93
,340183,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,55,66
,341329,ED_2b,ED2,55,381
,340020,OP_21,Median time to pain med,54,180
,340051,ED_2b,ED2,54,448
,340109,VTE_5,Warfarin therapy discharge instructions,54,26
,340131,OP_23,Head CT results,54,24
,340151,OP_20,Door to diagnostic eval,54,1191
,340069,OP_21,Median time to pain med,53,463
,340129,OP_21,Median time to pain med,53,179
,341318,OP_21,Median time to pain med,53,41
,341319,ED_2b,ED2,53,560
,341324,OP_23,Head CT results,53,17
,340024,ED_2b,ED2,52,457
,340075,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,52,56
,340145,OP_20,Door to diagnostic eval,52,432
,340147,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,52,25
,341327,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,52,12
,340017,OP_21,Median time to pain med,51,127
,340106,OP_21,Median time to pain med,51,35
,340120,OP_21,Median time to pain med,51,87
,340143,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,51,63
,340050,OP_23,Head CT results,50,18
,340156,ED_2b,ED2,50,250
,340186,OP_23,Head CT results,50,14
,341317,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,50,292
,341326,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,50,14
,340013,OP_21,Median time to pain med,49,186
,340050,OP_20,Door to diagnostic eval,49,293
,340098,ED_2b,ED2,49,452
,340130,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,49,35
,341316,OP_21,Median time to pain med,49,16
,340024,OP_23,Head CT results,48,21
,340039,OP_20,Door to diagnostic eval,48,370
,340042,OP_21,Median time to pain med,48,187
,340097,OP_21,Median time to pain med,48,96
,340158,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,48,12
,341303,OP_21,Median time to pain med,48,37
,341316,ED_2b,ED2,48,100
,340016,OP_21,Median time to pain med,47,160
,340021,OP_21,Median time to pain med,47,159
,340042,OP_20,Door to diagnostic eval,47,1810
,340090,OP_21,Median time to pain med,47,210
,340119,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,47,19
,340143,ED_2b,ED2,47,566
,340188,OP_20,Door to diagnostic eval,47,331
,340017,OP_20,Door to diagnostic eval,46,401
,340023,OP_20,Door to diagnostic eval,46,414
,340041,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,46,15
,340131,OP_20,Door to diagnostic eval,46,546
,341320,OP_21,Median time to pain med,46,44
,340114,OP_23,Head CT results,45,20
,341325,ED_2b,ED2,45,442
,341326,OP_21,Median time to pain med,45,87
,340041,OP_20,Door to diagnostic eval,44,385
,340064,ED_2b,ED2,44,503
,340091,OP_21,Median time to pain med,44,796
,340144,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,44,18
,341304,OP_21,Median time to pain med,44,23
,341319,OP_21,Median time to pain med,44,74
,341327,OP_21,Median time to pain med,44,83
,340040,OP_20,Door to diagnostic eval,43,406
,340098,OP_23,Head CT results,43,44
,340109,OP_21,Median time to pain med,43,159
,340171,OP_20,Door to diagnostic eval,43,481
,341322,ED_2b,ED2,43,390
,340017,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,42,18
,340021,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,42,39
,340053,OP_20,Door to diagnostic eval,42,481
,340087,OP_21,Median time to pain med,42,70
,340098,OP_20,Door to diagnostic eval,42,430
,340098,OP_21,Median time to pain med,42,322
,340099,OP_21,Median time to pain med,42,52
,340114,OP_21,Median time to pain med,42,89
,340186,OP_21,Median time to pain med,42,78
,341324,OP_21,Median time to pain med,42,129
,340142,OP_1,Median Time to Fibrinolysis,41,19
,340145,OP_21,Median time to pain med,41,140
,340003,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,40,16
,340145,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,40,28
,340123,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,39,27
,340166,OP_20,Door to diagnostic eval,39,438
,340173,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,39,19
,340064,OP_21,Median time to pain med,38,107
,340069,OP_20,Door to diagnostic eval,38,467
,340090,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,38,27
,340113,OP_20,Door to diagnostic eval,38,425
,340130,OP_23,Head CT results,38,21
,340183,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,38,17
,340187,OP_21,Median time to pain med,38,73
,341329,OP_21,Median time to pain med,38,52
,340166,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,37,27
,340002,OP_20,Door to diagnostic eval,36,407
,340075,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,36,18
,340126,OP_1,Median Time to Fibrinolysis,36,20
,340155,OP_20,Door to diagnostic eval,36,384
,341328,OP_20,Door to diagnostic eval,36,1049
,340040,OP_21,Median time to pain med,35,252
,340085,OP_20,Door to diagnostic eval,35,475
,340091,OP_20,Door to diagnostic eval,35,492
,340119,OP_20,Door to diagnostic eval,35,413
,340001,OP_20,Door to diagnostic eval,34,428
,340047,OP_21,Median time to pain med,34,334
,340050,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,34,74
,340070,OP_23,Head CT results,34,38
,340130,OP_20,Door to diagnostic eval,34,430
,340183,OP_20,Door to diagnostic eval,34,486
,341325,OP_1,Median Time to Fibrinolysis,34,12
,340068,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",33,52
,340126,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,33,21
,340143,OP_20,Door to diagnostic eval,33,500
,341320,OP_23,Head CT results,33,12
,341325,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,33,12
,341325,OP_20,Door to diagnostic eval,33,405
,340027,OP_20,Door to diagnostic eval,32,594
,340037,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,32,17
,340109,OP_23,Head CT results,32,34
,340123,OP_20,Door to diagnostic eval,32,407
,340115,OP_20,Door to diagnostic eval,31,432
,340116,OP_20,Door to diagnostic eval,31,485
,340142,OP_20,Door to diagnostic eval,31,407
,340020,OP_20,Door to diagnostic eval,30,466
,340020,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,30,14
,340030,OP_20,Door to diagnostic eval,30,384
,340090,OP_20,Door to diagnostic eval,30,387
,340096,OP_20,Door to diagnostic eval,30,377
,340126,OP_20,Door to diagnostic eval,30,438
,340141,OP_20,Door to diagnostic eval,30,240
,340147,OP_1,Median Time to Fibrinolysis,30,25
,340186,OP_20,Door to diagnostic eval,30,407
,341324,OP_20,Door to diagnostic eval,30,395
,340013,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,29,108
,340028,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,29,59
,340109,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,29,17
,340114,OP_20,Door to diagnostic eval,29,385
,340014,OP_21,Median time to pain med,28,186
,340085,OP_21,Median time to pain med,28,69
,340107,OP_1,Median Time to Fibrinolysis,28,11
,340107,OP_20,Door to diagnostic eval,28,406
,340151,OP_1,Median Time to Fibrinolysis,28,16
,340041,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,27,195
,340068,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,27,101
,340075,OP_20,Door to diagnostic eval,27,430
,340109,OP_1,Median Time to Fibrinolysis,27,23
,340060,OP_20,Door to diagnostic eval,26,422
,340084,OP_20,Door to diagnostic eval,26,431
,340142,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,26,19
,340147,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,26,333
,341318,OP_20,Door to diagnostic eval,26,404
,341324,OP_1,Median Time to Fibrinolysis,26,16
,341327,OP_20,Door to diagnostic eval,26,302
,340013,OP_1,Median Time to Fibrinolysis,24,13
,340051,OP_20,Door to diagnostic eval,24,381
,340068,OP_20,Door to diagnostic eval,24,382
,340158,OP_21,Median time to pain med,24,50
,340159,OP_21,Median time to pain med,24,59
,340047,OP_20,Door to diagnostic eval,23,596
,340064,OP_20,Door to diagnostic eval,23,381
,340127,OP_20,Door to diagnostic eval,23,707
,341304,OP_20,Door to diagnostic eval,23,403
,340015,OP_21,Median time to pain med,22,107
,340024,OP_20,Door to diagnostic eval,22,466
,340053,OP_21,Median time to pain med,22,181
,340061,OP_20,Door to diagnostic eval,22,380
,340120,OP_20,Door to diagnostic eval,22,401
,340173,OP_20,Door to diagnostic eval,22,466
,340183,OP_21,Median time to pain med,22,109
,340186,OP_1,Median Time to Fibrinolysis,22,12
,340073,OP_20,Door to diagnostic eval,21,380
,340087,OP_20,Door to diagnostic eval,21,406
,340184,OP_20,Door to diagnostic eval,21,468
,341303,OP_20,Door to diagnostic eval,21,424
,340013,OP_20,Door to diagnostic eval,20,430
,340032,OP_20,Door to diagnostic eval,20,403
,340037,OP_20,Door to diagnostic eval,20,440
,340106,OP_20,Door to diagnostic eval,20,422
,340014,OP_20,Door to diagnostic eval,19,1439
,340071,OP_20,Door to diagnostic eval,19,571
,340097,OP_20,Door to diagnostic eval,19,1495
,340133,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,19,47
,340144,OP_20,Door to diagnostic eval,19,425
,340158,OP_20,Door to diagnostic eval,19,481
,340109,OP_20,Door to diagnostic eval,18,2989
,340132,OP_20,Door to diagnostic eval,18,418
,340171,OP_21,Median time to pain med,18,151
,340003,OP_20,Door to diagnostic eval,17,523
,340023,OP_5,Median Time to ECG,17,50
,340127,OP_5,Median Time to ECG,17,128
,341325,OP_5,Median Time to ECG,17,131
,340010,OP_1,Median Time to Fibrinolysis,16,20
,340129,OP_20,Door to diagnostic eval,16,426
,341326,OP_20,Door to diagnostic eval,16,408
,340039,VTE_6,Hospital acquired potentially preventable venous thromboembolism,15,20
,341320,OP_20,Door to diagnostic eval,15,394
,340015,OP_20,Door to diagnostic eval,14,482
,340021,OP_20,Door to diagnostic eval,14,441
,340099,OP_5,Median Time to ECG,14,116
,340114,VTE_6,Hospital acquired potentially preventable venous thromboembolism,14,22
,340028,OP_20,Door to diagnostic eval,13,404
,340099,OP_20,Door to diagnostic eval,13,405
,340147,OP_5,Median Time to ECG,13,190
,340186,OP_5,Median Time to ECG,13,240
,340096,OP_5,Median Time to ECG,12,131
,340132,OP_5,Median Time to ECG,12,188
,340155,OP_5,Median Time to ECG,12,20
,340159,OP_20,Door to diagnostic eval,12,415
,340184,OP_5,Median Time to ECG,12,95
,341319,OP_20,Door to diagnostic eval,12,411
,341320,OP_5,Median Time to ECG,12,24
,340003,OP_5,Median Time to ECG,11,194
,340004,VTE_6,Hospital acquired potentially preventable venous thromboembolism,11,19
,340016,OP_5,Median Time to ECG,11,87
,340041,OP_5,Median Time to ECG,11,91
,341304,OP_5,Median Time to ECG,11,54
,340004,OP_5,Median Time to ECG,10,17
,340016,OP_20,Door to diagnostic eval,10,431
,340032,OP_5,Median Time to ECG,10,40
,340042,OP_5,Median Time to ECG,10,299
,340068,OP_5,Median Time to ECG,10,91
,340073,OP_5,Median Time to ECG,10,22
,340087,OP_5,Median Time to ECG,10,175
,340113,OP_5,Median Time to ECG,10,200
,340132,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",10,30
,340187,OP_20,Door to diagnostic eval,10,592
,341314,OP_20,Door to diagnostic eval,10,388
,341316,OP_20,Door to diagnostic eval,10,210
,341316,OP_5,Median Time to ECG,10,30
,341318,OP_5,Median Time to ECG,10,159
,341329,OP_20,Door to diagnostic eval,10,409
,340024,OP_5,Median Time to ECG,9,311
,340050,OP_5,Median Time to ECG,9,20
,340070,OP_5,Median Time to ECG,9,76
,340071,OP_5,Median Time to ECG,9,388
,340075,OP_5,Median Time to ECG,9,99
,340084,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,9,23
,340107,OP_5,Median Time to ECG,9,126
,341319,OP_5,Median Time to ECG,9,149
,341328,OP_5,Median Time to ECG,9,159
,340001,OP_5,Median Time to ECG,8,56
,340008,OP_5,Median Time to ECG,8,52
,340037,OP_5,Median Time to ECG,8,105
,340050,OP_22,Left before being seen,8,62955
,340051,OP_5,Median Time to ECG,8,67
,340091,OP_5,Median Time to ECG,8,39
,340098,OP_5,Median Time to ECG,8,95
,340106,OP_5,Median Time to ECG,8,20
,340115,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",8,65
,340123,OP_5,Median Time to ECG,8,110
,340142,OP_5,Median Time to ECG,8,97
,340155,VTE_6,Hospital acquired potentially preventable venous thromboembolism,8,12
,340166,OP_5,Median Time to ECG,8,184
,340188,OP_5,Median Time to ECG,8,78
,340010,OP_5,Median Time to ECG,7,276
,340028,VTE_6,Hospital acquired potentially preventable venous thromboembolism,7,46
,340030,OP_22,Left before being seen,7,76833
,340060,OP_5,Median Time to ECG,7,113
,340115,OP_5,Median Time to ECG,7,83
,340119,OP_5,Median Time to ECG,7,116
,340120,OP_5,Median Time to ECG,7,136
,340126,OP_5,Median Time to ECG,7,160
,340127,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",7,43
,340151,OP_5,Median Time to ECG,7,246
,340159,OP_5,Median Time to ECG,7,145
,340186,OP_22,Left before being seen,7,25378
,340187,OP_5,Median Time to ECG,7,182
,341303,OP_5,Median Time to ECG,7,39
,341315,OP_5,Median Time to ECG,7,115
,341326,OP_5,Median Time to ECG,7,142
,340020,OP_5,Median Time to ECG,6,126
,340027,OP_5,Median Time to ECG,6,75
,340069,OP_5,Median Time to ECG,6,192
,340143,OP_5,Median Time to ECG,6,30
,340144,OP_5,Median Time to ECG,6,20
,340145,OP_5,Median Time to ECG,6,181
,340147,VTE_6,Hospital acquired potentially preventable venous thromboembolism,6,32
,341329,OP_5,Median Time to ECG,6,127
,340001,OP_22,Left before being seen,5,117192
,340050,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",5,98
,340064,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",5,60
,340090,OP_5,Median Time to ECG,5,281
,340131,VTE_6,Hospital acquired potentially preventable venous thromboembolism,5,20
,340133,OP_5,Median Time to ECG,5,61
,340173,OP_5,Median Time to ECG,5,199
,341324,OP_5,Median Time to ECG,5,193
,340002,OP_22,Left before being seen,4,100655
,340013,OP_5,Median Time to ECG,4,127
,340015,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",4,48
,340017,OP_22,Left before being seen,4,31278
,340021,OP_5,Median Time to ECG,4,145
,340032,OP_22,Left before being seen,4,108844
,340039,OP_5,Median Time to ECG,4,72
,340040,OP_22,Left before being seen,4,125074
,340050,VTE_6,Hospital acquired potentially preventable venous thromboembolism,4,25
,340061,OP_22,Left before being seen,4,48357
,340064,OP_5,Median Time to ECG,4,145
,340084,OP_5,Median Time to ECG,4,225
,340085,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",4,54
,340087,OP_22,Left before being seen,4,21653
,340097,OP_5,Median Time to ECG,4,184
,340113,OP_22,Left before being seen,4,158758
,340116,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",4,55
,340123,OP_22,Left before being seen,4,43993
,340130,OP_5,Median Time to ECG,4,148
,340133,OP_22,Left before being seen,4,14730
,340141,VTE_6,Hospital acquired potentially preventable venous thromboembolism,4,57
,340143,OP_22,Left before being seen,4,54698
,340151,OP_22,Left before being seen,4,40310
,340171,OP_5,Median Time to ECG,4,67
,340171,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",4,50
,341328,OP_22,Left before being seen,4,18575
,340001,VTE_6,Hospital acquired potentially preventable venous thromboembolism,3,32
,340004,OP_22,Left before being seen,3,63064
,340008,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",3,34
,340013,OP_22,Left before being seen,3,36793
,340017,OP_5,Median Time to ECG,3,98
,340027,OP_22,Left before being seen,3,43279
,340030,VTE_6,Hospital acquired potentially preventable venous thromboembolism,3,126
,340042,OP_22,Left before being seen,3,62421
,340047,OP_22,Left before being seen,3,112056
,340051,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",3,39
,340053,OP_22,Left before being seen,3,98595
,340061,VTE_6,Hospital acquired potentially preventable venous thromboembolism,3,77
,340069,OP_22,Left before being seen,3,208625
,340070,OP_22,Left before being seen,3,70002
,340071,OP_22,Left before being seen,3,55098
,340075,OP_22,Left before being seen,3,59659
,340085,OP_22,Left before being seen,3,34097
,340090,OP_22,Left before being seen,3,80878
,340090,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",3,214
,340098,OP_22,Left before being seen,3,98150
,340107,OP_22,Left before being seen,3,29027
,340115,OP_22,Left before being seen,3,123144
,340126,OP_22,Left before being seen,3,51458
,340141,OP_22,Left before being seen,3,133503
,340147,OP_22,Left before being seen,3,72814
,340155,OP_22,Left before being seen,3,66293
,340166,OP_22,Left before being seen,3,99704
,340173,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",3,214
,340186,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",3,30
,341324,OP_22,Left before being seen,3,22953
,341324,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",3,32
,340001,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,262
,340003,OP_22,Left before being seen,2,38420
,340008,OP_22,Left before being seen,2,56344
,340010,OP_22,Left before being seen,2,65966
,340014,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,128
,340015,OP_22,Left before being seen,2,49147
,340015,OP_5,Median Time to ECG,2,14
,340020,OP_22,Left before being seen,2,39003
,340039,OP_22,Left before being seen,2,43125
,340040,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,42
,340041,OP_22,Left before being seen,2,29282
,340051,OP_22,Left before being seen,2,22259
,340060,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,50
,340068,OP_22,Left before being seen,2,29078
,340070,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,130
,340071,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,56
,340084,OP_22,Left before being seen,2,17096
,340091,OP_22,Left before being seen,2,109061
,340096,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,59
,340098,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,199
,340106,OP_22,Left before being seen,2,13772
,340109,OP_22,Left before being seen,2,45288
,340109,OP_5,Median Time to ECG,2,135
,340109,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,58
,340113,VTE_6,Hospital acquired potentially preventable venous thromboembolism,2,89
,340114,OP_22,Left before being seen,2,58608
,340119,OP_22,Left before being seen,2,34860
,340120,OP_22,Left before being seen,2,27597
,340126,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,46
,340127,OP_22,Left before being seen,2,23824
,340129,OP_22,Left before being seen,2,28583
,340130,OP_22,Left before being seen,2,76257
,340131,OP_22,Left before being seen,2,74427
,340132,OP_22,Left before being seen,2,24238
,340141,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,45
,340142,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,58
,340145,OP_22,Left before being seen,2,49366
,340151,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,65
,340158,OP_22,Left before being seen,2,31398
,340159,OP_22,Left before being seen,2,20115
,340171,OP_22,Left before being seen,2,49631
,340173,OP_22,Left before being seen,2,62926
,340183,OP_22,Left before being seen,2,36480
,340183,OP_5,Median Time to ECG,2,52
,341304,OP_22,Left before being seen,2,10755
,340002,VTE_6,Hospital acquired potentially preventable venous thromboembolism,1,70
,340004,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,212
,340014,OP_22,Left before being seen,1,134974
,340014,OP_5,Median Time to ECG,1,85
,340016,OP_22,Left before being seen,1,16186
,340020,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,81
,340021,OP_22,Left before being seen,1,68658
,340021,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,98
,340023,OP_22,Left before being seen,1,26919
,340024,OP_22,Left before being seen,1,34529
,340037,OP_22,Left before being seen,1,34511
,340042,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,122
,340047,VTE_6,Hospital acquired potentially preventable venous thromboembolism,1,108
,340053,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,116
,340060,OP_22,Left before being seen,1,30520
,340064,OP_22,Left before being seen,1,33310
,340073,OP_22,Left before being seen,1,47879
,340075,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,101
,340096,OP_22,Left before being seen,1,37872
,340099,OP_22,Left before being seen,1,23350
,340113,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,536
,340116,OP_22,Left before being seen,1,41528
,340129,OP_5,Median Time to ECG,1,49
,340131,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,136
,340142,OP_22,Left before being seen,1,40354
,340144,OP_22,Left before being seen,1,27392
,340184,OP_22,Left before being seen,1,27578
,341318,OP_22,Left before being seen,1,17386
,341319,OP_22,Left before being seen,1,17175
,341326,OP_22,Left before being seen,1,19142
,341327,OP_5,Median Time to ECG,1,54
,341329,OP_22,Left before being seen,1,15157
,340002,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,44
,340003,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,28
,340010,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,26
,340010,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,13
,340013,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,23
,340014,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,101
,340015,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,17
,340016,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,31
,340017,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,28
,340023,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,68
,340024,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,40
,340027,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,279
,340027,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,12
,340028,OP_22,Left before being seen,0,91030
,340028,OP_5,Median Time to ECG,0,13
,340028,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,122
,340030,OP_23,Head CT results,0,13
,340030,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,49
,340032,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,237
,340032,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,21
,340039,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,51
,340040,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,104
,340041,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,33
,340053,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,59
,340061,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,39
,340069,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,503
,340069,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,41
,340070,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,16
,340073,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,19
,340085,OP_5,Median Time to ECG,0,54
,340087,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,11
,340091,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,581
,340091,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,71
,340097,OP_22,Left before being seen,0,30813
,340097,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,55
,340098,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,14
,340099,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,39
,340107,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,39
,340114,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,112
,340115,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,38
,340116,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,17
,340119,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,58
,340120,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,42
,340123,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,74
,340129,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,28
,340130,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,92
,340133,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,30
,340142,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,17
,340143,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,209
,340144,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,26
,340145,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,29
,340147,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,148
,340151,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,11
,340155,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,40
,340158,OP_5,Median Time to ECG,0,51
,340158,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,29
,340166,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,138
,340173,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,11
,340183,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,22
,340183,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,13
,340184,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,18
,340187,OP_22,Left before being seen,0,12973
,341315,ED_2b,ED2,0,382
,341318,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,30
,341326,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,25
,341329,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,16
